aTyr Pharma Inc (NASDAQ:LIFE) has received a consensus rating of “Hold” from the six analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $1.18.

Several equities analysts have recently weighed in on LIFE shares. Citigroup raised shares of aTyr Pharma from a “sell” rating to a “neutral” rating and decreased their price target for the stock from $1.00 to $0.75 in a research note on Thursday, August 16th. Piper Jaffray Companies decreased their price target on shares of aTyr Pharma from $3.00 to $1.80 and set an “overweight” rating for the company in a research note on Monday, October 8th. BMO Capital Markets decreased their price target on shares of aTyr Pharma from $2.00 to $1.00 and set a “hold” rating for the company in a research note on Wednesday, August 15th. Finally, Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th.

In other news, Director Paul Schimmel bought 42,749 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The stock was acquired at an average cost of $0.74 per share, with a total value of $31,634.26. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jill Marie Broadfoot bought 64,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The stock was purchased at an average cost of $0.83 per share, with a total value of $53,120.00. The disclosure for this purchase can be found here. Insiders purchased 297,160 shares of company stock valued at $225,398 over the last three months. 25.00% of the stock is owned by company insiders.

An institutional investor recently raised its position in aTyr Pharma stock. Dimensional Fund Advisors LP lifted its position in aTyr Pharma Inc (NASDAQ:LIFE) by 33.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 114,449 shares of the biotechnology company’s stock after buying an additional 28,699 shares during the quarter. Dimensional Fund Advisors LP owned about 0.38% of aTyr Pharma worth $303,000 as of its most recent SEC filing. Institutional investors own 44.54% of the company’s stock.

Shares of LIFE traded down $0.05 during mid-day trading on Monday, hitting $0.63. 4,002,664 shares of the company’s stock were exchanged, compared to its average volume of 344,440. The stock has a market capitalization of $19.07 million, a P/E ratio of -0.34 and a beta of 2.88. aTyr Pharma has a 52 week low of $0.59 and a 52 week high of $4.35. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.26.

aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). On average, sell-side analysts anticipate that aTyr Pharma will post -1.29 earnings per share for the current fiscal year.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Featured Story: Investing strategies using the yield curve

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.